Rosuvastatin calcium (Crestor®) is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C.

The use of rosuvastatin (Crestor®) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Rosuvastatin calcium (Crestor®), a HMG-CoA reductase inhibitor, inhibits the rate-limiting enzyme in de novo cholesterol synthesis. HMG-CoA reductase inhibitors are frequently used to reduce the levels of plasma total cholesterol and low-density lipoprotein (LDL) cholesterol in individuals with hypercholesterolemia. It is believed that HMG-CoA reductase inhibitors lower cholesterol levels by reducing the production of mevalonic acid, which results in the following:

- A reduction in hepatic cholesterol synthesis
- A compensatory increase in the expression of high-affinity LDL receptors on hepatocyte membranes
- Stimulation of LDL catabolism

Rosuvastatin calcium (Crestor®) is approved when the following inclusion criteria is met:

- Documentation of a minimum 30-day trial and failure or contraindication/intolerance/allergy to one of the following agents:
  - a lovastatin-containing product
  - a pravastatin-containing product
  - a simvastatin-containing product

Rosuvastatin calcium (Crestor®) is denied when the following exclusion criteria is present:
• No documentation of a minimum 30-day trial and failure or contraindication/intolerance/allergy to one of the following agents:
  ○ a lovastatin-containing product
  ○ a pravastatin-containing product
  ○ a simvastatin-containing product

### Policy List of Applicable Drugs

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crestor</td>
<td>rosuvastatin</td>
</tr>
</tbody>
</table>

### Dosing and Administration

Refer to the specific manufacturer’s prescribing information for administration and dosage details for each specific agent.

### Policy References


Jones PH, Davidson MH, Stein EA, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosvuastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR...


